XLV declined 38bps last week, consolidating gains above 21-DMA ($145) support. Near-term resistance is $146.95 followed by all time highs of $148.27.
Author: Raj Gupta
Market View
The U.S. market remains in a Confirmed Uptrend. This week, indices rallied, with the S&P 500 and the Nasdaq rising 1.6% and 3.2%, respectively. The first level of support is at the rising 10-DMA (5,365/17,268), followed by the 21-DMA (5,326/17,054). The distribution day count stands at three and four, respectively.
O’Neil Health Care Weekly
XLV gained 1.9% for the week and is now testing near-term resistance at $146.95 before all-time highs of $148.27. Near-term support is along the rising 21-DMA ($144.35). Though the sector is the 5th best performer over the trailing 4-weeks (+2%), its RS line has yet to make a higher high, remaining in a longer-term downtrend. We will be looking for the sector to break into new highs before recommending an overweight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq are chopping around near all-time highs after
rallying ~1.3% and ~2.3%, respectively. The first level of support is at the rising 10-DMA (5,311/16,959), followed by the 21-DMA
(5,276/16,7687). The distribution day count stands at three and four, respectively.
O’Neil Health Care Weekly
XLV ended the week down 50bps, despite rallying 1.5% Friday to regain its 50-DMA ($142.78). This level will now act as near-term support with the range of resistance unchanged between $147 to $148.27 (all-time high). Its RS line (vs. the S&P 500 and Nasdaq) remains near lows, still warranting an underweight sector positioning.
Market View
The U.S. market remains in a Confirmed Uptrend. Indices closed lower this week, with the S&P 500 and the Nasdaq declining
0.5% and 1.1%, respectively. However, indices staged an upside reversal on Friday to close back above their 21-DMA (5,243/16592)
support after briefly trading below. Distribution days have clustered a bit with three and four, respectively over three weeks.
O’Neil Health Care Weekly
XLV declined 1.3% last week and is now sitting just above 21-DMA ($144) support with the next level at the rising 50-DMA ($143). The range of resistance is between $147 to $148.27 (all-time high). Its RS line (vs. the S&P 500 and Nasdaq) is near lows, still warranting an underweight sector positioning. XLV has now been underperforming the broader market for 18 straight months.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 was flat for the week while the Nasdaq rallied ~1.3%
higher led by the technology sector. Both indices remain at or near all-time highs with the 10-DMA (5,276/16,690) as the first
level of support. The distribution day count stands at two on each index.
O’Neil Health Care Weekly
XLV rallied nearly 2% for a second straight week and is now set to test new-high resistance between $147.70 to $148.27. The 21-DMA and 50-DMA are coinciding at $143 to act as downside support. Its RS line (vs. the S&P 500 and Nasdaq) continues to trade near lows, still warranting an underweight sector positioning.
Market View
The U.S. market has been upgraded to a Confirmed Uptrend. The upgrade was triggered as the S&P 500 and the Nasdaq gained 1.5% and 2.1%, respectively, and pushed back through their prior highs. Initial support at their 10-DMA (5,237/16,457), followed by the 21-DMA (5,187/16,267). There are no distribution days on the S&P 500 and one on the Nasdaq.